Answers are grounded in this paper and cite their sources.
Systematic review shows therapeutic agents from medicinal plants may improve schizophrenia symptoms, indicating a need for further research.
Ethnopharmacological Significance Schizophrenia, a complex psychiatric disorder with multifactorial etiology, profoundly affects patients’ behavior, cognition, affect, and thought processes. Given the stagnation in novel drug development, notable treatment‐related adverse effects, and suboptimal recovery rates, the identification of innovative therapeutic agents and strategies to mitigate side effects remains a critical unmet need. Preclinical advances have increasingly validated the scientific rationale for the clinical efficacy of medicinal plants. Consequently, the exploration of botanical antipsychotic agents has gained global traction due to their favorable safety profiles and emerging evidence of efficacy. Objective of the Review This review synthesizes a decade of preclinical and translational research on medicinal plants and traditional ethnomedicines for schizophrenia treatment. It provides a comprehensive analysis of the pharmacology and molecular mechanisms underlying the therapeutic potential of plant‐derived active ingredients, serving as a foundational resource for future drug development and clinical translation efforts. Materials and Methods A systematic literature review was conducted using PubMed, Web of Science, Elsevier, Scopus, SciFinder, Springer, and the China National Knowledge Infrastructure (CNKI). Search terms included “schizophrenia,” “traditional medicinal plants,” “Chinese materia medica,” “active ingredients,” and “phytochemicals.” Studies were selected based on their focus on natural products and ethnopharmacological interventions for schizophrenia published in the last decade. Following rigorous screening, data were categorized by plant‐derived bioactive compounds (e.g., flavonoids, polysaccharides, and alkaloids) and their mechanisms of action. Conclusions Natural products and traditional ethnomedicines constitute promising sources for novel antipsychotic drug development. Emerging evidence supports the translational potential of integrating phytotherapeutics into clinical practice, though significant gaps persist. Future research must prioritize comprehensive pharmacokinetic/toxicological profiling, standardized clinical trials, and mechanistic elucidation of plant‐derived compounds to realize their full therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: